Scholarlink

<p>Proteolysis-targeting chimeras (PROTACs) represent a transformative therapeutic modality that leverages the endogenous ubiquitin-proteasome system (UPS) to achieve targeted protein degradation. These heterobifunctional molecules facilitate the recruitment of E3 ubiquitin ligases to a protein of interest (POI), promoting its ubiquitination and subsequent proteasomal degradation. In contrast to conventional inhibitory approaches, PROTACs operate catalytically, enabling the degradation of a wide spectrum of targets—including those harboring drug-resistant mutations—at significantly lower doses. These attributes have positioned PROTACs as promising agents, particularly in oncology, where their efficiency and broad applicability have been increasingly demonstrated. Nonetheless, clinical translation of PROTACs faces challenges such as poor bioavailability, insufficient tumor-specific accumulation, and off-target effects. The integration of nanomedicine-based delivery platforms offers a viable path to overcome these limitations by enhancing drug stability, improving tissue selectivity, and reducing systemic toxicity. This review outlines the rational design principles underlying nano-PROTACs, highlights recent advances in nanoformulations aimed at optimizing their delivery and efficacy, discusses emerging combination regimens and innovative design strategies, and critically assesses the translational challenges and future directions of nano-PROTACs. Overall, nano-PROTAC technology has pioneered a brand-new approach in the field of disease treatment, providing unprecedented opportunities for precision medicine and personalized disease treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nano-PROTACs for precision medicine: engineering strategies for enhanced targeting and potency

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Xiaoping Yang,
  • Dongmei Wang,
  • Chunxiao Li,
  • Yujing Zhang,
  • Jinghua Yang,
  • Meng Liu,
  • Dongming Xing,
  • Wenqing Jiang,
  • Shengwei Xu,
  • Chao Wang

摘要

Proteolysis-targeting chimeras (PROTACs) represent a transformative therapeutic modality that leverages the endogenous ubiquitin-proteasome system (UPS) to achieve targeted protein degradation. These heterobifunctional molecules facilitate the recruitment of E3 ubiquitin ligases to a protein of interest (POI), promoting its ubiquitination and subsequent proteasomal degradation. In contrast to conventional inhibitory approaches, PROTACs operate catalytically, enabling the degradation of a wide spectrum of targets—including those harboring drug-resistant mutations—at significantly lower doses. These attributes have positioned PROTACs as promising agents, particularly in oncology, where their efficiency and broad applicability have been increasingly demonstrated. Nonetheless, clinical translation of PROTACs faces challenges such as poor bioavailability, insufficient tumor-specific accumulation, and off-target effects. The integration of nanomedicine-based delivery platforms offers a viable path to overcome these limitations by enhancing drug stability, improving tissue selectivity, and reducing systemic toxicity. This review outlines the rational design principles underlying nano-PROTACs, highlights recent advances in nanoformulations aimed at optimizing their delivery and efficacy, discusses emerging combination regimens and innovative design strategies, and critically assesses the translational challenges and future directions of nano-PROTACs. Overall, nano-PROTAC technology has pioneered a brand-new approach in the field of disease treatment, providing unprecedented opportunities for precision medicine and personalized disease treatment.

Graphical Abstract